U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310745) titled 'Low Dose Radiotherapy in Primary Indolent Cutaneous B-cell Lymphoma' on Dec. 16.
Brief Summary: Primary indolent cutaneous B cell lymphomas (PCBCL) are rare: although data on outcomes and treatment are limited, traditionally they have been treated with radiation doses in excess of 24 Gy. Recently, some trials that patients with primary cutaneous indolent lymphoma managed with very low dose (4 Gy) RT (LDRT) have shown that high response rates and durable remission can be achieved; unfortunately, given the retrospective nature of these studies, the role of LDRT in indolent PMCL remains undefined. The objective of this retrospective mu...